Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02005029 · ClinicalTrials.gov registry record · NA
Erythromycin in Parkinson's Disease
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02005029 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 18 participants.
The verdict
NCT02005029, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Gastroparesis (slow stomach emptying) is a common feature of Parkinson's Disease. Levodopa (Sinemet), a common medication for Parkinson's Disease, can make gastroparesis worse. Gastroparesis effects how the levodopa is absorbed and used by the body. This study will explore the possibility of using Erythromycin, a drug commonly used (off label) for gastroparesis, along with levodopa to determine if there is improved levodopa absorption and motor function.
Interventions
- DRUG placebo
- DRUG Erythromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02005029
The ClinicalTrials.gov registry entry for NCT02005029 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02005029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02005029 about?
NCT02005029 is a clinical study titled "Erythromycin in Parkinson's Disease". Gastroparesis (slow stomach emptying) is a common feature of Parkinson's Disease. Levodopa (Sinemet), a common medication for Parkinson's Disease, can make gastroparesis worse. Gastroparesis effects how the levodopa is absorbed and used by the body. This study will explore the possibility of using E...
What is the current status of trial NCT02005029?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2013-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02005029?
The interventions under investigation include: placebo (DRUG), Erythromycin (DRUG).
Who is sponsoring clinical trial NCT02005029?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.